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There is growing evidence that necrosis, instead of
apoptosis, could act as a natural adjuvant, which
could activate an immune response. In this work we
have investigated if induction of tumor necrosis
could trigger the af¯uence of in¯ammatory cells at
the tumor site, and thus induce an immune response.
For this purpose, a liquid N2 spray was applied on
human melanoma (IIB-MEL-J cell line) xenografted
in nude mice and 24 h later some mice received
intratumorally a single 500 U dose of recombinant
murine granulocyte macrophage-colony-stimulating
factor. 77±100% of the tumor mass underwent
necrosis. Congestion, edema, and endothelial cell
activation were the ®rst noticeable events. A quick
in®ltrative response of polymorphonuclear leuko-
cytes around the tumor was detected 24 h after
liquid N2 application, peaking at day 3. Massive
macrophage recruitment was observed since day 3.
An early intratumoral in®ltration with in¯ammatory
cells was only detected in the group that received
recombinant murine granulocyte macrophage-
colony-stimulating factor after necrosis induction by
liquid N2. Coexisting DEC 205- and F4/80-positive
cells increased in number, and their localization was
predominantly peritumoral after necrosis. Antibody
response was only detected in the groups with
tumor-induced necrosis. Our results suggest that
cryosurgery-induced necrosis could be a useful
model to analyze the interaction among necrosis,
in¯ammation, and the generation of an immune
response. Key words: cryosurgery/granulocyte-monocyte
colony-stimulating factor/in¯ammatory in®ltrate/mela-
noma. J Invest Dermatol 116:664±671, 2001
W
hereas primary human melanoma frequently
triggers a lymphoid reaction, this ability appears
to be lost in metastasis, as analysis of different
melanoma metastatic sites revealed scarce lym-
phoid in®ltration (Hernberg et al, 1997). The
reasons for this discrepancy are not known, but among several other
causes, the lack of lymphocytes arrival into tumors could be due to
an abortion of the immune response at the primary site by clonal
deletion of reacting lymphocytes or by the release of immunosup-
pressive factors by tumor cells (Morvillo et al, 1996). Even if
intratumoral lymphocytes are present, another mechanism that
tumor cells would employ to escape immune response would be
the downregulation of major histocompatibility complex class I
molecules. Along this line, when conditions for the priming of
tumor-speci®c response were examined in mice, no detectable
presentation of major histocompatibility complex class I restricted
tumor antigens by the tumor itself was found (Huang et al, 1994).
Rather, tumor antigens were exclusively cross-presented by bone
marrow derived antigen-presenting cells (APC) (Bennett et al,
1997). Although details on the cross-priming by APC and on the
underlying mechanisms that permit exogenous antigens to enter the
otherwise endogenous class I presentation pathway are not fully
characterized, it appears likely that the class I restricted antigens
should be accessible to the cross-presenting APC, in the form of
cell-associated debris or particulate in nature (Bennet et al, 1997).
The ®nal consequence of the interplay of these and other factors
is that the spontaneous immune response to progressing melanoma
is inef®cient. Our interest is to develop an ef®cient immune
response. It is accepted that apoptosis, as a normal physiologic
mechanism, proceeds without in¯ammation and would thus be
unable to generate an immune response. There is growing
evidence, instead, that necrosis could act as a natural adjuvant,
which could activate APC and initiate an immune response
(Gallucci et al, 1999).
Cryosurgery is a well-aimed and controlled procedure to induce
tissular necrosis by the application of liquid N2, and it was chosen as
it is rapid, ef®cient and the results could eventually be reproduced
in a clinical setting (Zouboulis, 1999). The biologic changes that
occur during and after cryosurgery have been studied in vitro and
in vivo (Orpwood, 1981; Mazur, 1984). Tissue injury is induced by
cell freezing and by the vascular stasis developed after thawing.
Therefore, the cryoreaction is characterized by physical and
vascular phases. A postulated third immunologic phase has not
been fully studied for malignant skin lesions (Zouboulis, 1999).
In order to study in the ®rst place the innate immune response,
which recent experiments point as essential in the development of
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an effective immune response (Clynes et al, 1998), we have
investigated if the rapid induction of necrosis in experimental
melanoma could trigger the af¯uence of in¯ammatory cells to the
tumor site and the induction of anti-tumoral antibody formation.
We also performed an exploratory approach to analyze if
intratumoral injection of recombinant murine granulocyte macro-
phage-colony-stimulating factor (rmGM-CSF) after cryosurgery
could enhance the af¯uence of dendritic cells (DC), which may
process necrotic cells and released antigens.
GM-CSF is a 24 kDa glycosylated cytokine (Burges et al, 1977)
that plays a vital part in various functions of the immune system.
Among its key activities, GM-CSF enhances macrophage cyto-
toxicity (Wing et al, 1989) and DC maturation (Szabolcs et al, 1996)
and migration (Shutt et al, 2000). These properties, found in vitro,
may constitute the basis for the bene®cial effect of GM-CSF when
different clinical and experimental approaches were studied.
Intralesional application of GM-CSF (Si et al, 1996), intradermal
administration of the cytokine for stage IV melanoma patients (Nasi
et al, 1999), GM-CSF-secreting tumor cells vaccines (Dranoff et al,
1993; Soiffer et al, 1998) or DC transduced with GM-CSF-
expressing viral vectors (Klein et al, 2000) have demonstrated
improved anti-tumoral responses.
MATERIALS AND METHODS
Cell lines MCF-7 (human adenocarcinoma) (Soule et al, 1973); B16-
F1 (murine melanoma) kindly provided by Dr A. Vecchi, Milan, Italy;
1G11 (murine microvascular endothelium) (Dong et al, 1997); IIB-
MEL-J (Guerra et al, 1989); IIB-MEL-IAN and IIB-MEL-LES
(Kairiyama et al, 1995) (human melanoma) cell lines were employed.
Every cell line was cultured according to the indications reported in the
original publications, and they were all tested to be mycoplasm free. IIB-
MEL-J was also grown subcutaneously in nude mice (IIB-MEL-Jnude)
and maintained by in vivo passages.
Animals Athymic male NIH (S)-nu, 6±8 wk old, were obtained from
the Faculty of Veterinary Sciences Facility (University of La Plata,
Buenos Aires).
Tumors To produce IIB-MEL-J tumors, approximately 1 mm3 tumor
fragments were subcutaneously implanted by trocar in the left leg.
Animals were controlled weekly until tumors were visually detected.
Mice were treated when the tumors measured less than 10 mm in their
largest dimension. Animals were randomly assigned to control and
treatment groups (n = 3±4 animals per group per experiment). At least
three experiments were performed.
For evaluation of tumor growth, measures were taken with caliper
before treatment and on being killed. Tumor sizes are expressed
following the formula (A 3 B2)/2, where A is the largest and B is the
shortest dimension.
Treatment groups Groups treated with cryosurgery: animals were
anesthetized with an intraperitoneal injection of 0.3 ml of 5 mg per ml
sodium pentobarbital. An intermittent liquid N2 spray (Cry-A-C device,
Brymill, Ellington, CT) was applied by an experienced dermatologist
(JMa) on the skin over the tumor during a time adjusted to tumor size.
The maximum application time to the larger tumors was 45 s. The spray
was emitted from a distance of 1±2 cm from the target at a 90° angle. A
needle thermocouple was placed with its tip at the periphery of the
tumor to evaluate the temperature reached during freezing. After the
procedure, mice were kept on a heating pad until they recovered from
anesthesia. This point in treatment was taken as day 0. One day later,
one group of mice received a single dose of 500 U rmGM-CSF (EC50:
0.12 ng per ml) (Sigma, St Louis, MO) applied intratumorally with a
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G needle tuberculin syringe (Terumo Medical Corporation, Elkton,
MD).
Control groups All the animals were anesthetized. A group of tumor-
bearing mice remained untreated. For the group only receiving rmGM-
CSF, one intratumoral dose was applied as described above. To evaluate
the effect of the intratumoral injection itself or in conjunction with
necrosis, one group of tumor-bearing mice were injected with
phosphate-buffered saline (PBS) ±0.1% bovine serum albumin (BSA;
vehicle used for rmGM-CSF reconstitution). In another group, animals
were cryotreated previous to vehicle injection. Animals from all groups
were killed on days 3 or 15.
Tissue and sera processing Before being killed, blood was drawn by
cardiac puncture from anesthetized mice. After clotting and centrifug-
ation, sera were fractionated and stored at ±80°C. For every group,
tumors were bisected: one-half of each specimen was ®xed in 10%
buffered formalin, embedded in paraf®n, sectioned at 4±7 mm and
stained with hematoxylin±eosin. The other half was frozen and stored at
±80°C for immunohistochemistry. Brie¯y, cryostat sections were
acetone-®xed, blocked with 5% normal rabbit serum and incubated with
optimal dilutions of the primary monoclonal antibodies (MoAb). Rat
anti-mouse MoAb used were RB6±5CG (Pharmingen, San Diego, CA)
for polymorphonuclear leukocytes (PMN), F4/80 (Serotec Ltd, U.K.) for
macrophages, TMb-1 and DEC 205 (hybridoma supernatant, kindly
provided by Dr A. Vecchi, Istituto Mario Negri, Milan, Italy) for natural
killer cells and DC, respectively. The speci®c binding was revealed using
1/100 goat anti-rat IgG (Sigma), 1/500 rat peroxidase/anti-peroxidase
complex (Accurate Chemicals) and 0.05% 3,3¢-diaminobenzidine (Sigma)
plus 0.03% H2O2. Endogenous peroxidase activity was blocked with
0.3% H2O2.
Humoral response This was determined by enzyme-linked immuno-
sorbent assay and immuno¯uorescence. Enzyme-linked immunosorbent
assay was performed as previously described (Capurro et al, 1998). Brie¯y,
104 exponentially growing IIB-MEL-J cells were plated in 96-well plates
and left overnight for adherence. They were then washed twice with PBS,
®xed for 10 min with 4% buffered formalin and washed again three times
with PBS. The wells were blocked with PBS±1% BSA for 1 h, after
which 1/25 and 1/50 dilutions of mice sera were incubated overnight at
4°C. After washing three times with PBS±0.1% BSA, a peroxidase-
conjugated rabbit anti-total mouse immunoglobulin (Dako Corporation,
CA) 1/250 was added for 90 min. After washing several times with PBS±
0.1% BSA, the reaction was developed with o-phenylenediamine and read
at 415 nm.
The immuno¯uorescence assay was performed as described (BallareÂ
et al, 1995). Brie¯y, 4% formalin-®xed cells were blocked with 10%
normal goat serum. Mice sera were used as above and speci®c binding
was detected with ¯uorescein isothiocyanate goat anti-mouse antibody
(Sigma).
Quantitative evaluations Determinations were performed with an
image analyzer (KS 300 Kontron Electronik) coupled to an Axioplan
microscope (Zeiss, Germany). The distance (in mm) between the basal
membrane of the epidermis and the tumor border was measured in 10
®elds per sample at 325 magni®cation. Total tumor and necrotic areas
were evaluated under the same conditions. PMN and macrophages were
counted in at least 10 ®elds per sample at 31000 magni®cation (high-
power ®eld, HPF).
Statistical analysis Data on in®ltrating cells (PMN and macrophages)
were established by computing medians and ranks for each group
examined. Tests for differences between pretreatment and post-treatment
levels were calculated using the nonparametric Wilcoxon rank test. Data
on tumor growth, edema, and necrosis were statistically analyzed using
the Student's t test (two-tailed).
RESULTS
Sequential morphologic analysis The time course of the
reaction to freezing in tumor-bearing mice after cryosurgery was
initially analyzed in order to determine the presence and nature of
in¯ammatory cells and other noncellular accompanying events.
The results are summarized in Table I. Congestion, edema, and
endothelial cells activation were the ®rst noticeable events, as early
as 1.5 h after liquid N2 spray. At this time an early response of
PMN leukocytes, which were densely recruited intravascularly
with scarce or null extravasation was also noticed. Later on, PMN
massively in®ltrated the peritumoral area and reached their maximal
concentration at day 3. At day 15, these cells had notoriously
decreased. Macrophages were scarcely observed 24 h postliquid N2
application, became more abundant at day 3 and peaked at day 7,
persisting until the end of the observation period. The histologic
identities of these cells were con®rmed immunohistochemically
with MoAb RB6-5CG for PMN (not shown) and MoAb F4/80
for macrophages (Fig 1A, B).
Both intratumoral and peripheral vascular endothelium were also
affected. Hyperplastic, swelling cells with epithelioid appearance
were early morphologic evidences of endothelium activation.
Fifteen days later, intratumoral endothelium (Table I) reversed to a
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less activated phenotype displaying plane morphology. In untreated
tumor samples, only plane endothelial cells were observed. Early
vascular damage could be assumed by the presence of erythrocyte
extravasation until day 3 post-treatment.
Accompanying these cellular events, a rapid edema (1.5 h)
(Table I) was recorded that slowly decreased from day 7 until the
end of the observation period. Stromal peritumoral ®broblasts
showed an inverse kinetics, increasing in size and number from days
7 to 15. Collagen accumulation was a late phenomenon.
Considering these observations, days 3 and 15 were selected to
analyze the in®ltrative phenomenon in more detail and to evaluate
the effect of rmGM-CSF.
Treatment groups The characteristics of the treatments
received by different groups are listed in Table II. rmGM-CSF
was injected intratumorally, as the main objective was to investigate
if DC could enter the necrotic mass and thus enhance the immune
response.
Tumor growth, necrosis, and edema Whereas tumors from
groups I, III, and V continued growth between days 3 and 15
(Fig 2), tumor progression was arrested in groups subjected to
cryosurgery (II, IV, and VI); however, in these groups, complete
regression was only observed in six of 20 mice, in which tumor
tissue was completely replaced by necrotic masses and ®brosis.
As it refers to necrosis from group I, histologic examination at
day 3 revealed viable tumor cells, a well de®ned boundary between
tumor and dermis and absence of edema (Fig 3A). Examination of
tumors from groups II and IV at day 3 showed signi®cant necrosis
of the tumor mass, ranging from 77 to 100% (Figs 3B and 4).
Viable tumor cells as judged by hematoxylin±eosin staining,
however, were still present and their regrowth probably accounted
for the diminution in percentages of necrosis at day 15 (Fig 4).
Edema was only detected in mice from groups II, IV, and VI
(Fig 5). This is in accordance with an important af¯ux of
in¯ammatory cells in®ltrating the dermis between epidermis and
tumor (Fig 3C). The distance between the epidermis and tumor
border in cryotreated groups remained almost unchanged at day 15
as initial edema was substituted by reparative tissue and collagen
deposition (Fig 5).
Evaluation of the in®ltrate A more detailed analysis of the
in®ltrate to quantitate the two predominant populations, PMN and
macrophages, is presented in Table III.
Peritumorally, a signi®cant increase of PMN was found in
cryotreated groups with respect to controls, with up to 150 PMN
per HPF. The macrophage population was also signi®cantly
recruited to the periphery of the tumor. It was possible to ®nd
almost 150 macrophages per HPF in areas of maximal in¯ux
(Table III). This af¯ux was apparently mostly due to necrosis, as
neither the addition of rmGM-CSF (Table III, group IV) or
vehicle (Table III, group VI) increased peritumoral PMN and
macrophage accumulation. The distribution of in¯ammatory cells
was not homogeneous in the deep dermis of groups II and IV, as
even within highly in®ltrated areas, denser clusters of PMN and
macrophages were found.
In group III (rmGM-CSF alone), peritumoral macrophages were
signi®cantly more abundant than in the untreated tumor-bearing
mice (group I), although less than in groups II and IV. A similar
response to rmGM-CSF could probably be also taking place in
group IV, although the high density of in®ltration evoked by
necrosis could be masking this effect. At the end of the observation
period (day 15) the density of the peripheral in®ltrate was much less
than at day 3, but still signi®cantly higher for groups II and IV.
Intratumorally (Table III), the in®ltration of PMN and
macrophages was less important than at the periphery, with less
than 34 and 37 cells per HPF, respectively. In this environment,
necrosis by itself does not appear to have the same potency of
recruitment, as group II showed no signi®cant difference with
respect to control groups; however, although a single injection of
rmGM-CSF coupled to cryosurgery had no additive effect on
tumor-surrounding in®ltrate, the intratumoral recruitment was
signi®cantly augmented. Both PMN and macrophages were more
abundant when compared not only with controls but also to group
II. At day 15, tumor cell in®ltration in group IV was still
signi®cantly higher with respect to control groups. This suggests
that rmGM-CSF combined to necrosis favors a lasting intratumoral
in®ltration.
Concerning natural killer cell in®ltrates, no signi®cant augmen-
tation was found after 3 d. The scarce presence of natural killer cells
occurred peritumorally only in some cryotreated tumors (data not
shown). Cryotreated groups attained 35 natural killer cells per 100
HPF as compared with 0±7 natural killer cells per 100 HPF present
in the dermis of control samples.
A comparative study between macrophages and DC was
performed in tumor samples from day 3 (Fig 1). In tumors from
group I, scarce Langerhans cells in the epidermis (not shown) and
scattered macrophages and DEC205-positive cells were visualized
in the dermis (Fig 1A, C). Similar results were obtained for tumors
from group V (data not shown). In group III, injected with rmGM-
CSF, the number of DEC 205-positive cells with varied morph-
ology augmented in the basal layer of epidermis and in dermis (data
not shown). Macrophages also changed their localization to
peritumoral areas, consistent with data reported above in the
quantitative analysis of this group. When necrosis was induced F4/
80 staining pattern changed dramatically. There was not only an
augmented number of positive cells (Fig 1B), but also an increased
intensity of staining. DEC 205-positive cells (putative DC) were
Table I. Time course of some morphologic changes postcryosurgerya
Time post-treatment Macrophages PMN
Tumor
necrosis Fibroblasts Congestion Edema Collagen
Activated
ECd
Day ±1 (untreated) ± ± ± + no no Unmodi®ed no
1.5 h 6 6 6c + +++ ++++ Unmodi®ed +
+++b
6.5 h 6 +++ 6c + +++ ++++ Unmodi®ed +
Day 1 + +++ 6c + +++ ++++ Unmodi®ed +
Day 3 +++ ++++ ++++ + +++ +++ Unmodi®ed ++
Day 7 ++++ ++ ++++ ++ +++ ++ ++ ++
Day 15 +++ + ++ +++ no + ++++ +
aData correspond to semiquantitative evaluations in the periphery of the tumor on hematoxylin±eosin sections. Two independent experiments were performed in
triplicate.
bCells observed in the lumen of vessels.
cTumor cells depicting initial evidence of necrosis.
dEC, endothelial cells.
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only found to increase in tumor-surrounding dermis (Fig 1D).
Remarkably, DEC 205-positive/F4/80-negative clusters were
occasionally found within dermic venules (Fig 1B, D, insets).
Humoral response To determine whether cryosurgery resulted
in the generation of antibodies recognizing human melanoma cells,
we screened mice sera by enzyme-linked immunosorbent assay
assays. Signi®cant augmentation of reactivity with respect to
untreated tumor-bearing mice was observed in eight of 20 mice
from cryotreated groups II and IV. A nonsigni®cant level of
positivity was found for groups I, III, and V (Fig 6A). Serum
samples from the different groups were analyzed for antibody
isotypes by immunodiffusion (data not shown). Only IgM and
IgG3 isotypes were detected with varying relative amounts in
different animals. IgG3 augmentation was only detected in some
sera from groups II and IV.
The speci®city of antibodies was also tested by immuno¯uores-
cence. Mice sera from groups II and IV revealed an intense
reactivity against IIB-MEL-J cells as compared with a faint
positivity obtained with sera from group I (Fig 6B, D). Normal
sera were completely nonreactive. The same intense positivity
against IIB-MEL-J obtained with sera from group II was also
observed against the human melanoma cell lines IIB-MEL-IAN
and IIB-MEL-LES and the human mammary adenocarcinoma cell
line MCF-7. Positivity was also found against human lymphocytes
but not monocytes, suggesting that the antibodies developed could
be partially directed against normal human antigens. Positivity
Figure 1. Comparative analysis of macro-
phages and DC populations 3 d post-
treatment. (A) Immunohistochemical detection
for F4/80-positive macrophages in the tumor-
adjacent dermis from a group I mouse. (B) A
representative area from a group IV mouse
showing the peritumoral adjacent dermis densely
populated with F4/80-positive cells. Inset: F4/80-
negative in¯ammatory cells at the lumen of a
dermic vessel. (C) Immunohistochemical staining
for DEC 205-positive cells performed in con-
secutive sections from the same tumor depicted in
(A). (D) an increased number of DC close to
necrotic areas is observed in peritumoral dermis
from a group IV mouse. Inset: Cells within the
same vessel as in (B) demonstrate intense positivity
for DEC 205. Scale bar : 2.5 mm; insets, 2.27 mm.
Table II. Description of experimental groups
Animals/group
Groups Day 3 Day 15 Treatment
I 8 9 Untreated tumor-bearing mice
II 8 10 Cryosurgery only
III 8 10 Local rmGM-CSF
IV 8 10 Cryosurgery + local rmGM-CSF
V 8 8 Vehicle
VI 8 8 Cryosurgery + vehicle
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against murine cell lines was extremely weak and showed no
differences among groups I, II, and IV (Table IV).
DISCUSSION
Rapid freezing and slow thawing is the key strategy for cell
destruction by cryosurgery (Orpwood, 1981; Mazur, 1984; Turk
et al, 1999; Zouboulis, 1999). Various cell populations present
distinct abilities to tolerate cold, and melanocytes are the most
sensitive skin cells to low temperatures. The consequent membrane
disruption and cellular contents release could behave as attracting
signals to in¯ammatory cells. Within hours, we observed a very
rapid response of PMN to injury, with densely populated vessels
but scarce extravasation. Rapid morphologic changes of endothelial
cells such as hyperplasia, swelling, and nuclei protrusion to the
lumen would indicate an activated state, as also reported by others
(Cotran and Pober, 1988). The probable induction of selectins
(Springer, 1994) would promote PMN adhesion to endothelial cells
and subsequent extravasation around and within the tumor. At a
later phase macrophages were also recruited, their more abundant
number being attained 3 d later, and their persistence at the tumor
site being longer lasting than PMN. These results diverge from
those obtained by Turk et al (1999) after cryosurgery in a prostate
cancer model, where the in¯ammatory in®ltrate was no longer
present at 72 h. It is interesting to note that the timing and some of
the events evoked by cryosurgery-induced necrosis are very similar
to the necrosis and in¯ammatory reaction generated by other
treatments to human melanoma, such as limb perfusion with tumor
necrosis factor-a and melphalan (Nooijen et al, 1998). This
similarity suggests that once tumor necrosis is established, the
ensuing in¯ammatory mechanisms could be similar.
It has recently been reported that necrotically killed cells activate
endogenous signals of distress responsible for the recruitment of
DC, stimuli that would not be generated by healthy or
apoptotically dying cells (Gallucci et al, 1999). Even more, exposure
of immature DC to those stimuli provides maturation signals,
critical for the initiation of immunity (Sauter et al, 2000). Our
results are consistent with this evidence because when necrosis was
provoked by cryosurgery, changes in DC quantity and distribution
were recorded. Migration from the epidermis to the deeper layers
of the dermis would re¯ect an acquired ability of these cells to
present antigens in their transit to the draining lymph node (Kimber
et al, 2000).
It is also important to point out the increased macrophage
population and their probable activated state, suggested by the
increase in reactivity to MoAb F4/80 (see Fig 1B), as conse-
quences of cryosurgical treatment in our experimental model. This
evidence does not lack relevance as not only DC may act as APC,
but some in¯ammatory monocytes became macrophages at the
subcutaneous tissue and after phagocytosis could differentiate into
lymph node DC (Randolph et al, 1999). The concomitant
existence of PMN and macrophages could be bene®cial because,
as it has been hypothesized (Wells and Malkovsky, 2000), when
tumor cells die, the released intracellular contents, including heat
shock proteins, could activate neighboring PMN to produce
proin¯ammatory cytokines and recruit APC. Heat shock proteins
complexed with tumor-derived antigenic peptides would be taken
up by activated macrophages and in turn cross-presented to tumor-
speci®c T cells via major histocompatibility complex class I
(Bennett et al, 1997).
Figure 3. Tumor histologic examination. Hematoxylin±eosin
staining of representative mice killed at day 3. (A) Tumor from group I
with well-de®ned peritumoral and tumor areas. (B) Representative tumor
from group II with extensive intratumoral necrotic area and ®brous
surrounding tissue with an important leukocyte in®ltration. (C ) Tumor
from group IV showing a high density of vessels and in¯ammatory
in®ltrate around them. Scale bar: (A, B ) 5 mm; (C ) 2.5 mm.
Figure 2. Tumor sizes when animals were killed. Data correspond
to tumor sizes taken at day 3 (light bars) and at day 15 (dark bars) and
are expressed as mean 6 SEM (n = 8±10 animals per group). Treatments
applied to groups I±VI are described in Table II. *p = 0.03 (day 3 vs
day 15, group I), p = 0.02 (day 3 vs day 15, group III), and p = 0.03
(day 3 vs day 15, group V).
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Our preliminary results on GM-CSF addition to cryosurgically
treated tumors are promising, as an early intratumoral arrival of
in¯ammatory cells would be favored. The immunostimulatory
effect of this cytokine is being increasingly characterized, with
evidence stemming from clinical and experimental approaches.
Comparison between these approaches is extremely dif®cult,
however; for instance, with respect to intratumoral injection of
GM-CSF (Si et al, 1996; Nasi et al, 1999), the intratumoral doses
administered in clinical trials (i.e., 10±80 mg per injection per
tumor site; Nasi et al, 1999) could hardly be attained in murine
models for tumors of similar size due to several orders of magnitude
difference in total weight and the probable ensuing toxicity.
Finally, the observation that an antibody response was triggered
in cryosurgically treated mice, but not in untreated mice is highly
relevant, as antibodies may play a part in anti-tumoral defense
through complement activation or antibody-dependent cell-
mediated cytotoxicity. In our experimental setting, antibody
response is probably T cell independent. Nonetheless, some nude
mice preserve a small rudimentary cystic thymus (Hsu et al, 1975),
which could account for the low levels of IgG2a antibodies
occasionally found (data not shown). It should be taken into
account, however, that the switch IgM±IgG3 is T cell independent
(Mongini et al, 1982).
The antibody response observed in this xenograft model is
predictably directed against normal human antigens, probably as
well as against tumor antigens because both would be seen as ``non-
self'' molecules by the nude mice. The presence of speci®c
antibodies targeting tumor cells and a dense granulocyte in®ltration
would contribute to tumor cell death. Local antibody-dependent
cell-mediated cytotoxicity could be potentiated in the presence of
GM-CSF by priming granulocytes for greater cytotoxicity
(Kushner and Cheung, 1989).
The results obtained in this study suggest that this model may
provide a clearer picture of the mechanisms that could be used to
increase intratumoral leukocyte in®ltration, and these studies
should be pursued and extended to immunocompetent models
for a full comprehensive analysis.
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Table III. In¯ammatory cells quantitationa
Peritumoral Intratumoral
PMNb Mb PMNb Mb
Groups Day 3 Day 15 Day 3 Day 15 Day 3 Day 15 Day 3 Day 15
I 0 0 1 0 0 0 0 0
(0±5) (0±5) (0±9) (0±3) (0±1) (0±5) (0±2) (0±3)
II 20c 1c 12c 9c 0 0 0 0
(2±150) (0±20) (3±150) (0±28) (0±12) (0±4) (0±2) (0±3)
III 0 0 3c 0 0 0 1 0
(0±8) (0±16) (0±19) (0±9) (0±1) (0±5) (0±6) (0±2)
IV 20c 1 13c 4c 2cd 1c 2cd 2c
(2±150) (0±58) (3±100) (0±30) (0±34) (0±14) (0±37) (0±11)
V 0 0 0 0 0 0 0 0
(0±4) (0±3) (0±2) (0±3) (0±2) (0±4) (0±1) (0±5)
VI 20c 1c 12c 5c 0 0 0 0
(2±150) (0±15) (0±150) (0±28) (0±10) (0±4) (0±2) (0±3)
aValues (cells per HPF) are expressed as medians. Ranks are shown in brackets.
bPolymorphonuclear leukocytes (PMN) and macrophages (M) were evaluated in at least 10 ®elds per mice.
c(p = 0.01); compared with untreated group (Wilcoxon test).
d(p = 0.01); compared with cryotreated group (Wilcoxon test).
Figure 4. Image analysis of tumor necrosis. Quantitations were
performed with an image analyzer in samples at day 3 (light bars) and
day 15 (dark bars). One representative experiment of three is shown.
Treatments applied to groups I±VI are described in Table II.
Figure 5. Image analysis of peritumoral edema. Distances (in mm)
between epidermis and tumor were measured at day 3 (light bars) and
day 15 (dark bars). The horizontal dotted line indicates the distance in
nontreated animals. Above this line, the existence of edema is assumed.
Measurements were performed at original magni®cation, 3 25 in 10
®elds per sample. Treatments groups are described in Table II.
*p < 0.01.
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Table IV. Analysis of speci®city of mice reactive seraa
Cell type Cell line PBS Group I sera Group II sera Group IV sera
Human melanoma IIB-MEL-J ± + +++ +++
Human melanoma IIB-MEL-IAN ± 6 +++ +++
Human melanoma IIB-MEL-LES ± + +++ ++
Human breast adenocarcinoma MCF-7 ± + +++ ++
Human peripheral blood
mononuclear cells
± 6 +/++ (Ly)b
± (Mo)b
+/++ (Ly)b
± (Mo)b
Murine melanoma Bl6-F1 ± + + +
Murine microvascular
endothelial cells
1G11 ± 6 6 6
aData correspond to semiquantitative evaluations performed in immuno¯uorescence assays using mycoplasma-free cell lines. Three independent experiments were done.
bFreshly isolated lymphocytes (Ly) and monocytes (Mo) from a healthy donor were used as normal human cell control.
Figure 6. Antibody generation by cryosurgery treatment. (a) Immunoreactivity of sera evaluated by enzyme-linked immunosorbent assay. Values
for groups I, III, and V correspond to eight to 10 animals. For groups II and IV, only positive sera (four of 10 mice for each group) are represented.
Sera from group VI were not tested for reactivity. Normal mice serum was also assayed (sn). *p < 0.004, as compared with groups I, III, and V. (b)
Representative immuno¯uorescence with reactive sera from groups II and IV was performed as described under Materials and Methods. (c) Phase contrast
image corresponding to b. (d) Representative immuno¯uorescence with sera from group I. (e) Phase contrast image corresponding to d. Scale bar :
11.11 mm.
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